[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368931-105":59,"doc-detail-368931-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","discovering-anticancer-drug-target-combinations-via-network-informed-signaling-based-approach","Discovering anticancer drug target combinations via network-informed signaling-based approach","","Oncologists face difficult choices when selecting anticancer drug combinations for individual patients, because single-agent treatments often trigger resistance and existing combination options are limited by scant clinical experience. The study presents a network-informed signaling-based strategy using protein-protein interaction networks and shortest paths to infer co-target combinations. It tests real patient-derived breast and colorectal cancer data and identifies targets such as alpelisib plus LJM716 and alpelisib plus cetuximab plus encorafenib to reduce tumors. Results suggest a way to overcome resistance by selecting alternative pathway co-targets and connectors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/discovering-anticancer-drug-target-combinations-via-network-informed-signaling-based-approach/368931/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/discovering-anticancer-drug-target-combinations-via-network-informed-signaling-based-approach/368931.png","ImageObject",300,407,{"name":92,"@type":93},"Guten tag","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are optimal anticancer drug combinations difficult to determine?","Question",{"text":112,"@type":113},"Single-drug targeting commonly fails due to inherent or emergent resistance, and sequential regimens often repeat the resistance cycle. Existing combination choices are largely empirical and constrained by limited clinical experience.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What method does the study use to select drug target combinations?",{"text":117,"@type":113},"It develops a strategy that analyzes protein-protein interaction networks with shortest paths to identify communication pathways and infer key co-target combinations that mimic signaling used to bypass blocked pathways during drug resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What drug target combinations does the approach identify and test?",{"text":121,"@type":113},"The strategy is tested on patient-derived breast and colorectal cancer data, including combinations such as alpelisib + LJM716 for breast cancer and alpelisib + cetuximab + encorafenib for colorectal cancer, which diminish tumors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368931,1790393867,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","A Nature Portfolio journal  \n[https://doi.org/10.1038/s43856-025-01150-9](https://doi.org/10.1038/s43856-025-01150-9)  \nDiscovering anticancer drug target combinations via network-informed signaling-based approach  \n Check for updates  \n\n| Bengi Ruken Yavuz 1, Hyunbum Jang1,2 & Ruth Nussinov 1,2,3  |  |  |\n| --- | --- | --- |\n| Abstract\u003Cbr>Background Oncologists deciding on cancer treatments must makedifﬁcult decisions as to which prescription and implementation strategies would best suit each patient. Much is still unknown about combinations of prescription drugs as there are many to choose from. Atthe outset, the oncologist reckons with at least two established facts: (i) patients receiving successive single molecules treatments are likely to experience drug resistance, and (ii), to select optimal drug combinations requires to pick the ‘best’ protein drug target combinations. Intuitively, target selection should precede drug selection, implying that wellinformed strategies would opt to ﬁrst consider drug targets — not drugs — combinations. Nowadays, drug combinations that oncologists consider are empirical and limited. They are restricted primarily by observations and praxis, that is, scant clinical experience with their application.\u003Cbr>Methods Here we develop a strategy for selecting optimal drug target combinations following nature. We use protein-protein interaction networksand shortest paths to discover communication pathways in cells based on interaction network topology. Our strategy mimics cancer signaling in drug resistance, which commonly harnesses pathways parallel to those blocked by drugs, thereby bypassing them.\u003Cbr>Results We select key communication nodes as combination drug targets inferred from topological features of networks. We test our network-informed signaling-based approach to discover anticancer drug target combinations on available clinical data, patient-derived breast and colorectal cancers. Alpelisib + LJM716 and alpelisib + cetuximab + encorafenib combinations diminish tumors in breast and colorectal cancers, respectively.\u003Cbr>Conclusions Our network-based approach discovers optimal protein co-target combinations to counter resistance, selecting co-targets from alternative pathways and their connectors. |  | Plain Language Summary\u003Cbr>Cancer treatment often involves drug combinations, but choosing the right ones is difﬁcult. Oncologists know that using one drug at a time can result in resistance. However, current drug combinations are mostly based on limited clinical experience. This study suggests that choosing the right targets for treatment is key to success and introduces a new method that helps identify the best combinations, based on analysis of cancer cells’ adaptation to treatment. We tested our method using real data from breast and colorectal cancer patients. Our strategy can help oncologists design smarter drug combinations to overcome resistance. |\n| Precision oncology is increasingly transitioning towards drug combinations1–4. However, determining the optimal combinations is challenging. Single drug targeting a single protein (monotherapy) frequently succumbs because of inherent or emergent resistance5–7. The critical challenge in cancer treatment lies in completely eradicating tumor cells before they can develop and propagate resistant mutations3,8. Sequential singledrug regimens are unlikely to overcome this hurdle, as they merely repeat the cycle of resistance development. In contrast, by simultaneously | administering multiple therapeutic agents, oncologists can dramatically reduce the probability of individual cancer cells developing simultaneous resistance to multiple drugs2,3. The multi-targeted intervention essentially creates a more formidable therapeutic barrier against the cancer’s adaptive potential.\u003Cbr>Targeting pathways with small-molecule inhibitors has proven a compelling strategy. Over 80 drugs targeting kinases are FDA-approved, several approved in 20239. However, canc","cbCaivN59jBDFGP6","https://ap.wps.com/l/cbCaivN59jBDFGP6","pdf",5929884,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Precision oncology and resistance challenge\n## Monotherapy and sequential regimens\n## Rationale for multi-target combinations\n# Network-informed approach","[{\"question\":\"Why are optimal anticancer drug combinations difficult to determine?\",\"answer\":\"Single-drug targeting commonly fails due to inherent or emergent resistance, and sequential regimens often repeat the resistance cycle. Existing combination choices are largely empirical and constrained by limited clinical experience.\"},{\"question\":\"What method does the study use to select drug target combinations?\",\"answer\":\"It develops a strategy that analyzes protein-protein interaction networks with shortest paths to identify communication pathways and infer key co-target combinations that mimic signaling used to bypass blocked pathways during drug resistance.\"},{\"question\":\"What drug target combinations does the approach identify and test?\",\"answer\":\"The strategy is tested on patient-derived breast and colorectal cancer data, including combinations such as alpelisib + LJM716 for breast cancer and alpelisib + cetuximab + encorafenib for colorectal cancer, which diminish tumors.\"}]","Discovering anticancer drug target combinations via network-informed signaling-based approach | PDF",1790179258,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8762c73e50f57ab2ace607929531b326.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/075af658cb8b3b5d627151560d4fd316.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1dc25536c2a5f928561f01ddbc8071a.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46b10cd9ac204ffe319938882695f80c.webp",980,1301]